LAUSR

Intravenous therapy with iloprost is a mainstay of the treatment of systemic sclerosis-related Raynaud’s phenomenon (SSc-RP), and it is currently advised by the European Lea-gue Against Rheumatism (EULAR) recommendation (1). Here, we describe the case of a patient with systemic sclerosis (SSc) who developed paradoxical Raynaud’s phenomenon (RP) following iloprost infusion. The patient, a 70-year-old man and a non-smoker, was diagnosed with limited cutaneous systemic sclerosis (lcSSc) in January 2006, with vascular (RP without digital ulcers), cutaneous, and oesophageal involvement, and positivity for anti-centromere antibodies and anti- β 2 -GPI antibodies.